Jemma J A Anderson1,2, Jennifer J Couper1,2, Lynne C Giles3, Catherine E Leggett1,4, Roger Gent5, Brian Coppin6, Alexia S Peña1,2. 1. Discipline of Paediatrics, Robinson Research Institute, University of Adelaide, Australia. 2. Endocrinology and Diabetes Department, Women's and Children's Hospital, Australia. 3. School of Public Health, Faculty of Health and Medical Sciences, University of Adelaide, Australia. 4. Pharmacy, Women's and Children's Hospital, Australia. 5. Medical Imaging, Women's and Children's Hospital, Australia. 6. Flinders Medical Centre, Bedford Park, Australia.
Abstract
Context:Children with type 1 diabetes have vascular dysfunction preceding atherosclerosis. Early interventions are needed to reduce cardiovascular disease. Objective: To evaluate the effect of metformin on vascular function in children with type 1 diabetes. Design: Twelve-month double-blind, randomized, placebo-controlled trial. Setting: Tertiary pediatric diabetes clinic. Participants: Ninety children (8 to 18 years of age), >50th percentile body mass index (BMI), with type 1 diabetes. Intervention: Metformin (up to 1 g twice a day) or placebo. Main Outcome Measure: Vascular function measured by brachial artery ultrasound [flow-mediated dilatation/glyceryl trinitrate-mediated dilatation (GTN)]. Results:Ninety participants were enrolled [41 boys, 13.6 (2.5) years of age, 45 per group], 10 discontinued intervention, and 1 was lost to follow-up. On metformin, GTN improved, independent of glycosylated hemoglobin (HbA1c), by 3.3 percentage units [95% confidence interval (CI) 0.3, 6.3, P = 0.03] and insulin dose reduced by 0.2 U/kg/d (95% CI 0.1, 0.3, P = 0.001) during 12 months, with effects from 3 months. Metformin had a beneficial effect on HbA1c at 3 months (P = 0.001) and difference in adjusted HbA1c between groups during 12 months was 1.0%; 95% CI 0.4, 1.5 (10.9 mmol/mol; 95% CI 4.4, 16.4), P = 0.001. There were no effects on carotid/aortic intima media thickness, BMI, lipids, blood pressure, or other cardiovascular risk factors. Median (95% CI) adherence, evaluated by electronic monitoring, was 75.5% (65.7, 81.5), without group differences. More gastrointestinal side effects were reported on metformin (incidence rate ratio 1.65, 95% CI 1.08, 2.52, P = 0.02), with no difference in hypoglycemia or diabetic ketoacidosis. Conclusions: Metformin improved vascular smooth muscle function and HbA1c, and lowered insulin dose in type 1 diabetes children. These benefits and good safety profile warrant further consideration of its use.
RCT Entities:
Context:Children with type 1 diabetes have vascular dysfunction preceding atherosclerosis. Early interventions are needed to reduce cardiovascular disease. Objective: To evaluate the effect of metformin on vascular function in children with type 1 diabetes. Design: Twelve-month double-blind, randomized, placebo-controlled trial. Setting: Tertiary pediatric diabetes clinic. Participants: Ninety children (8 to 18 years of age), >50th percentile body mass index (BMI), with type 1 diabetes. Intervention: Metformin (up to 1 g twice a day) or placebo. Main Outcome Measure: Vascular function measured by brachial artery ultrasound [flow-mediated dilatation/glyceryl trinitrate-mediated dilatation (GTN)]. Results: Ninety participants were enrolled [41 boys, 13.6 (2.5) years of age, 45 per group], 10 discontinued intervention, and 1 was lost to follow-up. On metformin, GTN improved, independent of glycosylated hemoglobin (HbA1c), by 3.3 percentage units [95% confidence interval (CI) 0.3, 6.3, P = 0.03] and insulin dose reduced by 0.2 U/kg/d (95% CI 0.1, 0.3, P = 0.001) during 12 months, with effects from 3 months. Metformin had a beneficial effect on HbA1c at 3 months (P = 0.001) and difference in adjusted HbA1c between groups during 12 months was 1.0%; 95% CI 0.4, 1.5 (10.9 mmol/mol; 95% CI 4.4, 16.4), P = 0.001. There were no effects on carotid/aortic intima media thickness, BMI, lipids, blood pressure, or other cardiovascular risk factors. Median (95% CI) adherence, evaluated by electronic monitoring, was 75.5% (65.7, 81.5), without group differences. More gastrointestinal side effects were reported on metformin (incidence rate ratio 1.65, 95% CI 1.08, 2.52, P = 0.02), with no difference in hypoglycemia or diabetic ketoacidosis. Conclusions: Metformin improved vascular smooth muscle function and HbA1c, and lowered insulin dose in type 1 diabeteschildren. These benefits and good safety profile warrant further consideration of its use.
Authors: Petter Bjornstad; Michal Schäfer; Uyen Truong; Melanie Cree-Green; Laura Pyle; Amy Baumgartner; Yesenia Garcia Reyes; Aristides Maniatis; Sunil Nayak; R Paul Wadwa; Lorna P Browne; Jane E B Reusch; Kristen J Nadeau Journal: Circulation Date: 2018-12-18 Impact factor: 29.690
Authors: Ida Pastore; Andrea Mario Bolla; Laura Montefusco; Maria Elena Lunati; Antonio Rossi; Emma Assi; Gian Vincenzo Zuccotti; Paolo Fiorina Journal: Int J Mol Sci Date: 2020-07-12 Impact factor: 5.923
Authors: Evgenia Gourgari; Jeanette M Stafford; Ralph D'Agostino; Lawrence M Dolan; Jean M Lawrence; Amy Mottl; Catherine Pihoker; Elaine M Urbina; R Paul Wadwa; Dana Dabelea Journal: Ann Pediatr Endocrinol Metab Date: 2019-09-30
Authors: Evgenia Gourgari; Jeanette M Stafford; Ralph D'Agostino; Lawrence M Dolan; Jean M Lawrence; Santica Marcovina; Lina Merjaneh; Amy K Mottl; Amy S Shah; Dana Dabelea Journal: Pediatr Diabetes Date: 2020-05-05 Impact factor: 3.409